Publications

SCI(E) Journal Articles
  1. Hyeong-Geun Jo, Kyeoul Jeong , Ji-Young Ryu, Soyun Park, Yun-Seok Choi, Won-Gun Kwack, Yeo-Jin Choi and Eun-Kyoung Chung. Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database. Journal of Personalized Medicine 2022; 12(1), 5
  2. Choi YJ, Yang SW, Kwack WG, Lee JK, Lee TH, Jang JY, Chung EK (Correspondence). Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea. Pharmaceuticals 2021;14;783.
  3. Han HS, Lee HH, Gil HS, Chung KS, Kim JK, Kim DH, Yoon J, Chung EK, Lee JK, Yang WM, Shin YK, Ahn HS, Lee SH, Lee KT. Standardized hot water extract from the leaves of Hydrangea serrata (Thunb.) Ser. alleviates obesity via AMPK pathway and modulating gut microbiota composition in high fat diet- induced obese mice. Food Funct 2021;12;2672-2685.
  4. Lee J, Chung EK, Kang SW, Lee HJ, Rhie SJ. Quantification of Teicoplanin Using the HPLC-UV Method for Clinical Applications in Critically Ill Patients in Korea. Pharmaceutics 2021;13;1-10.
  5. Park S, Geum MJ, Choi HJ, Kim CJ, Kwack WG, Chung EK (Co-Correspondence), Rhie SJ. Validation of a questionnaire for patient awareness and the need for a community-based outpatient antimicrobial stewardship program (O-asp): A pilot study. Antibiotics 2021;10;441
  6. Lee YM, Ryu BH, Hong SI, Cho OH, Hong KW, Bae IG, Kwack WG, Kim YJ, Chung EK, Kim DY, Lee MS, Park KH. Clinical impact of early reinsertion of a central venous catheter after catheter removal in patients with catheter-related bloodstream infections. Infect Control Hosp Epidemiol 2021;42;162-168.
  7. Jang E, Lee JK, Inn KS, Chung EK, Lee KT, Lee JH. Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice. Healthcare 2021;8;417.
  8. Choi YJ, Kim MH, Chung EK (Co-Correspondence), Lee JK, Yoon JM, Yug JS, Jang DK. Prevalence and seriousness of analgesic-induced adverse events in Korea: A 10-year nationwide surveillance. J Patient Saf 2020;16;E215-E224.
  9. Yoo HJ, Hwang SJ, Lee JH, Shim WS, Choi YW, Cho SM, Chung EK (Co-correspondence), Park JB, Lee KT. Development and validation of LC-MS/MS method for the determination of 2′,4′,6′- trihydroxyacetophenone and its application to a pharmacokinetic study in rats and dogs. Molecules 2020;25;4373.
  10. Choi HY, Cho KH, Jin C, Lee JE, Kim TH, Jung WS, Moon SK, Ko CN, Cho SY, Jeon CY, Choi TY, Lee MS, Lee SH, Chung EK, Kwon S. Exercise therapies for Parkinson’s disease: A systematic review and meta-analysis. Parkinsons Dis 2020;2020:2565320.
  11. Yoon J, Kwack WG, Shim WS, Lee JK, Jang DK, Gu N, Cho JY, Lee KT, Chung EK (Co-correspondence). Quantitation of plasma and biliary cefpiramide concentrations in human samples using high-performance liquid chromatography. Biomed Chromatogr 2020;34;e4957.
  12. Gee MS, Son SH, Jeon SH, Do J, Kim N, Ju YJ, Lee SJ, Chung EK, Inn KS, Kim NJ, Lee JK. A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse. Alzheimers Res Ther 2020;12:45.
  13. Yoon J, Kang SW, Shim WS, Lee JK, Jang DK, Gu N, Kim SK, Lee KT, Chung EK (Co-correspondence). Quantification of metronidazole in human bile fluid and plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2020;1138:121959.
  14. Jung SY, Yug JS, Clarke JM, Bauer TM, Keedy VL, Hwang S, Kim SJ, Chung EK (Co-correspondence), Lee JI. Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2020;85:173-183.
  15. Park S, Kang JE, Choi HJ, Kim CJ, Chung EK, Kim SA, Rhie SJ. Antimicrobial stewardship programs in community health systems perceived by physicians and pharmacists: A qualitative study with gap analysis. Antibiotics (Basel) 2019;8:252.
  16. Yang S, Hwang SJ, Park JY, Chung EK (Co-correspondence), Lee JI. Association of genetic polymorphisms of NAT2, CYP2E1, GSTM1, GSTT1, and SLCO1B1 with the risk of anti-tuberculosis drug- induced liver injury: a systematic review and meta-analysis. BMJ Open 2019;9:e027940.
  17. Jung S, Chung EK (Co-first author), Jun MS, Son ES, Rhie SJ. Differences in colistin administration and bacterial and treatment outcomes in critically ill patients. Sci Rep 2019;9:8781.
  18. Park JM, Chae SI, Noh YS, Lee SJ, Shim WS, Yoon JM, Hwang SJ, Lee KT, Chung EK (Correspondence). Pharmacokinetics and bioequivalence of two fenofibrate choline formulations in healthy subjects under fed and fasted condition. Int J Clin Pharmacol Ther 2019;57:217-228.
  19. Chae SI, Yoo HJ, Lee SY, Chung EK, Shim WS, Lee KT. Development and validation of simple LC-MS- MS assay for the quantitative determination of ticagrelor in human plasma: its application to a bioequivalence study. J Chromatogr Sci 2019;57:331-338.
  20. Lee JI, Jung SY, Yug JS, Chung EK, Keedy VL, Bauer TM, Clarke JM, Hurwitz H, Lee H, Park N, Lee S, Kim HK, Baek I, Hwang S, Nam SY, Ha I, Kim SJ. Population pharmacokinetics of a novel TGF-beta receptor I kinase inhibitor vactosertib in patients with advanced-stage solid tumors. 2019;105;S103.
  21. Chung EK, Lee JH, Jang DK, Lee SH, Lee JH, Park BJ, Kwon K, Lee JK. Causative agents of drug- induced pancreatitis: a nationwide assessment. Pancreas 2018;47:1328-1336.
  22. Cho KH, Kim TH, Kwon S, Jung WS, Moon SK, Ko CN, Cho SY, Jeon CY, Lee SH, Choi TY, Jun JH, Choi J, Lee MS, Chung EK. Complementary and Alternative Medicine for Idiopathic Parkinson’s Disease: An Evidence-Based Clinical Practice Guideline. Front Aging Neurosci 2018;10:323.
  23. Cho KH, Kim TH, Jung WS, Moon SK, Ko CN, Cho SY, Jeon CY, Choi TY, Lee MS, Lee SH, Chung EK, Kwon S. Pharmacoacupuncture for idiopathic Parkinson’s disease: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2018;2018:3671542.
  24. Jung SY, Lee SH, Lee SY, Yang S, Noh H, Chung EK (Co-correspondence), Lee JI. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill paients: a systematic review and Bayesian network meta-analysis. Critical Care 2017;21:319.
  25. Kim JI, Park SW, Lim JJ, Sohn SI, Shin JS, Park SC, Jang YP, Chung EK, Lee HW, Lee KT. Gastroprotective effects of the isopropanol extract of Artemisia princeps and its gastroretentive floating tablets on gastric mucosal injury. Acta Pharm 2017;67:479-494.
  26. Cho KH, Kim TH, Kwon S, Jung WS, Moon SK, Ko CN, Cho SY, Jeon CY, Lee SH, Choi TY, Lee MS, Chung EK, Kim M. Moxibustion for idiopathic Parkinson’s disease: A systematic review and meta- analysis of randomized controlled trials. European Journal of Integrative Medicine 2017;13:26-33.
  27. Chung EK, Cheatham SC, Fleming MR, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of doripenem in obese critically ill and non-critically ill patients. Ann Pharmacother 2017;51:209-218.
  28. Chung EK, Cheatham SC, Fleming MR, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of meropenem in obese and non-obese patients. J Clin Pharmacol 2017;57:356-368.
  29. Park YH, Park JM, Chung EK, Lee SY, Shim WS, Lee KT. Development of liquid chromatography tandem mass spectrometry method for determination of mazindol in human plasma: application to a bioequivalence study of Daewon Sanorex Tablet® (mazindol 1 mg). Curr Pharm Anal 2017;13:559-565.
  30. Ryu JH, Kim JI, Kim HS, Noh GJ, Lee KT, Chung EK (Co-correspondence). Pharmacokinetic interactions between pelubiprofen and eperisone hydrochloride: a randomized, open-label, crossover study of healthy Korean men. Clin Ther 2017;39:138-149.
  31. Kim DW, Weon KY, Hong EP, Chung EK, Lee KT. Comparative physicochemical and pharmacokinetic properties of quetiapine and its active metabolite norquetiapine. Chem Pharm Bull (Tokyo) 2016;64:1546- 1554.
  32. Seo S, Lee KG, Shin JS, Chung EK, Lee JY, Kim HJ, Lee KT. 6′-O-Caffeoyldihydrosyringin isolated from Aster glehni suppresses lipopolysaccharide-induced iNOS, COX-2, TNF-α, IL-1β and IL-6 expression via NF-κB and AP-1 inactivation in RAW 264.7 macrophages. Bioorg Med Chem Lett 2016;26:4592-4598.
  33. Chung EK, Muloma E, Osterholzer D, Atkinson K, Erdman SM. Development and implementation of a pharmacist- managed outpatient parenteral antimicrobial therapy (OPAT) program in a county teaching hospital. Am J Health Syst Pharm 2016;73:e24-33.
  34. Nichols KR, Chung EK, Knoderer CA, Dees J, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin, administered with tazobactam, in critically ill children. Antimicrob Agents Chemother 2015;60:522-531.
  35. Hwang HJ, Ryu JH, Yim SV, Chung EK, Shim WS, Park JS, Shin JS, Lee KT. Development of a simple and accurate RP-HPLC-UV for determination of choleretic drug alibendol in human plasma and its application for a pharmacokinetic study. Curr Pharm Anal 2016;12:244-248.
  36. Choi ID, Ryu JH, Lee DE, Lee MH, Shim JJ, Ahn YT, Sim JH, Huh CS, Shim WS, Yim SV, Chung EK, Lee KT. Enhanced absorption study of ginsenoside compound K (20-O-𝛽-(D-Glucopyranosyl)-20(S)- protopanaxadiol) after oral administration of fermented red ginseng extract (HYFRG™) in healthy Korean volunteers and rats. Evid Based Complement Alternat Med 2016; Article ID 3908142.
  37. Shin JS, Ryu S, Jang DS, Cho YW, Chung EK, Lee KT. Amomum tsao-ko fruit extract suppresses lipopolysaccharide-induced inducible nitric oxide synthase by inducing heme oxygenase-1 in macrophages and in septic mice. Int J Exp Pathol 2015;96:395-405
  38. Chung EK, Cheatham SC, Fleming MR, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in morbidly obese and non-obese patients. J Clin Pharmacol 2015;55:899-908.
  39. Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother 2014;48:178-186
  40. Cheatham SC, Fleming MR, Healy DP, Chung EK, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacokinetics of meropenem in morbidly obese, hospitalized patients. J Clin Pharmacol 2014;54:324-330
  41. Cheatham SC, Fleming MR, Healy DP, Chung CEK, Shea KM, Humphrey ML, Kays MB. Steady-State pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013;41:52-56
  42. Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, and Lee SY. CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 2012;68:149-154
NON-SCI(E) Journal Articles
  1. Kim DH, Cho JY, Chae SI, Kang BK, An TG, Shim WS, Noh YS, Hwang SJ, Chung EK, Lee KT. Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. Transl Clin Pharmacol 2017;25:173-178.